Cardiol Therapeutics (CRDL) shares were down 15.9% in recent Wednesday trading after the company said topline results from a phase 2 trial of CardiolRx showed a "notable" improvement in extracellular volume, with "no significant difference" in global longitudinal strain among patients with preserved left ventricular function at baseline.
Extracellular volume and global longitudinal strain, measured after 12 weeks of double-blind therapy, were the two primary endpoints of the study, the company said.
Cardiol said the results of the study provide clinical proof of concept for CardiolRx and support advancing its clinical development and that of CRD-38, another investigational drug, in cardiomyopathies, heart failure, and myocarditis.
CardiolRx was also observed to be safe and well-tolerated, the company added.
Price: 1.14, Change: -0.22, Percent Change: -15.93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.